HER family inhibitors in pancreatic cancer: current status and future directions

Bibliography

• JEMAL A, SIEGEL R, WARD E et al.: Cancer statistics, 2006. CA Cancer J. Clin. (2006) 56(2):106-130.
   PubMed Web of Science ®Google Scholar
• ROTHENBERG ML, MOORE MJ, CRIPPS MC et al.: A Phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer. Ann. Oncol. (1996) 7(4):347-353.
   PubMed Web of Science ®Google Scholar
• CARMICHAEL J, FINK U, RUSSELL RC et al.: Phase II study of gemcitabine in patients with advanced pancreatic cancer. Br. J. Cancer (1996) 73(1):101-105.
   PubMed Web of Science ®Google Scholar
• BURRIS HA III, MOORE MJ, ANDERSEN J et al.: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J. Clin. Oncol. (1997) 15(6):2403-2413.
   PubMed Web of Science ®Google Scholar
• CASCINU S, GASPARINI G, CATALANO V et al.: A Phase I-II study of gemcitabine and docetaxel in advanced pancreatic cancer: a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD). Ann. Oncol. (1999) 10(11):1377-1379.
   PubMed Web of Science ®Google Scholar
• VAN MOORSEL CJ, PINEDO HM, VEERMAN G et al.: Mechanisms of synergism between cisplatin and gemcitabine in ovarian and non-small cell lung cancer cell lines. Br. J. Cancer (1999) 80(7):981-990.
   PubMed Web of Science ®Google Scholar
• LOUVET C, LABIANCA R, HAMMEL P et al.: Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD Phase III trial. J. Clin. Oncol. (2005) 23(15):3509-3516.
   PubMed Web of Science ®Google Scholar
• ROCHA LIMA CM, ROTCHE R, JEFFERY M et al.: A randomized Phase III study comparing efficacy and safety of gemcitabine and irinotecan to gemcitabine alone in patients with locally advanced or metastatic pancreatic cancer who have not received prior systemic therapy (abstract). Proc. Am. Soc. Clin. Oncol. (2003) 22:251a.
   Google Scholar
• CONROY T, PAILLOT B, FRANCOIS E et al.: Irinotecan plus oxaliplatin and leucovorin-modulated fluorouracil in advanced pancreatic cancer-a Groupe Tumeurs Digestives of the Federation Nationale des Centres de Lutte Contre le Cancer study. J. Clin. Oncol. (2005) 23(6):1228-1236.
   PubMed Web of Science ®Google Scholar
• WELLS A: EGF receptor. Int. J. Biochem. Cell Biol. (1999) 31(6):637-643.
   PubMed Web of Science ®Google Scholar
• ARTEAGA CL: The epidermal growth factor receptor: from mutant oncogene in nonhuman cancers to therapeutic target in human neoplasia. J. Clin.Oncol. (2001) 19(18 Suppl.):32S-40S.
   PubMed Web of Science ®Google Scholar
• YARDEN Y, SLIWKOWSKI MX: Untangling the ErbB signaling network. Nat. Rev. Mol. Cell. Biol. (2001) 2(2):127-137.
   PubMed Web of Science ®Google Scholar
• MOTOYAMA AB, HYNES NE, LANE HA: The efficacy of ErbB receptor-targeted anticancer therapeutics is influenced by the availability of epidermal growth factor-related peptides. Cancer Res. (2002) 62(11):3151-3158.
   PubMed Web of Science ®Google Scholar
• FRIEDLANDER E, ARNDT-JOVIN DJ, NAGY P, JOVIN TM, SZOLLOSI J, VEREB G: Signal transduction of erbB receptors in trastuzumab (Herceptin) sensitive and resistant cell lines: local stimulation using magnetic microspheres as assessed by quantitative digital microscopy. Cytometry A. (2005) 67(2):161-171.
   PubMedGoogle Scholar
• XIONG HQ, ABBRUZZESE JL: Epidermal growth factor receptor-targeted therapy for pancreatic cancer. Semin. Oncol. (2002) 29:31-37.
   PubMed Web of Science ®Google Scholar
• LEMOINE NR, HUGHES CM, BARTON CM et al.: The epidermal growth factor receptor in human pancreatic cancer. J. Pathol. (1992) 166(1):7-12.
   PubMed Web of Science ®Google Scholar
• YAMANAKA Y, FRIESS H, KOBRIN MS et al.: Coexpression of epidermal growth factor receptor and ligands in human pancreatic cancer is associated with enhanced tumor aggressiveness. Anti-Cancer Res. (1993) 13(3):565-569.
   PubMed Web of Science ®Google Scholar
• DONG M, NIO Y, GUO KJ et al.: Epidermal growth factor and its receptor as prognostic indicators in Chinese patients with pancreatic cancer. Anti-Cancer Res. (1998) 18(6B):4613-4619.
   PubMed Web of Science ®Google Scholar
• YARDEN Y: The EGFR family and its ligands in human cancer: signaling mechanisms and therapeutic opportunities. Eur. J. Cancer. (2001) 37(Suppl. 4):S3-S8.
   PubMed Web of Science ®Google Scholar
• CRAVEN RJ, LIGHTFOOT H, CANCE WG: A decade of tyrosine kinases: from gene discovery to therapeutics. Surg. Oncol. (2003) 12(1):39-49.
   PubMed Web of Science ®Google Scholar
• LEVITZKI A: Protein tyrosine kinase inhibitors as novel therapeutic agents. Pharmacol. Ther. (1999) 82(2-3):231-239.
   PubMed Web of Science ®Google Scholar
• OSHEROV N, LEVITZKI A: Epidermal-growth-factor-dependent activation of the src-family kinases. Eur. J. Biochem. (1994) 225(3):1047-1053.
   PubMedGoogle Scholar
• MENDELSOHN J, BASELGA J: Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J. Clin. Oncol. (2003) 21(14):2787-2799.
   PubMed Web of Science ®Google Scholar
• NORMANNO N, BIANCO C, DE LUCA A, MAIELLO MR, SALOMON DS: Target-based agents against ErbB receptors and their ligands: a novel approach to cancer treatment. Endocr. Relat. Cancer (2003) 10(1):1-21.
   PubMed Web of Science ®Google Scholar
• IWATA K, PROVONCHA K, GIBSON N: Inhibition of mutant EGFRvIII transformed cells by tyrosine kinase inhibitor OSI-774 (Tarceva). Proc. Am. Soc. Clin. Oncol. (2002):Abstract 79.
   Google Scholar
• MOYER JD, BARBACCI EG, IWATA KK et al.: Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase. Cancer Res. (1997) 57(21):4838-4848.
   PubMed Web of Science ®Google Scholar
• SOULIERES D, SENZER NN, VOKES EE, HIDALGO M, AGARWALA SS, SIU LL: Multicenter Phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J. Clin. Oncol. (2004) 22(1):77-85.
   PubMed Web of Science ®Google Scholar
• HIDALGO M: Erlotinib: preclinical investigations. Oncology (2003) 17(11 Suppl. 12):11-16.
   PubMedGoogle Scholar
• DURKIN AJ, OSBORNE DA, YEATMAN TJ, ROSEMURGY AS, ARMSTRONG C, ZERVOS EE: EGF receptor antagonism improves survival in a murine model of pancreatic adenocarcinoma. J. Surg. Res. (2006) 135(1):195-201
   PubMed Web of Science ®Google Scholar
• DURKIN AJ, BLOOMSTON PM, ROSEMURGY AS et al.: Defining the role of the epidermal growth factor receptor in pancreatic cancer grown in vitro. Am. J. Surg. (2003) 186(5):431-436.
   PubMed Web of Science ®Google Scholar
• NG SS, TSAO MS, NICKLEE T et al.: Effects of the epidermal growth factor receptor inhibitor OSI-774, Tarceva, on downstream signaling pathways and apoptosis in human pancreatic adenocarcinoma. Mol. Cancer Ther. (2002) 1(10):777-783.
   PubMed Web of Science ®Google Scholar
• MOORE MR: Brief communication: a new combination in the treatment of advanced pancreatic cancer. Semin. Oncol. (2005) 32(6 Suppl. 8):5-6.
   PubMed Web of Science ®Google Scholar
• MOORE MJ, GOLDSTIN D, HAMM J et al.: Erlotinib improves survival when added to gemcitabine in patients with advanced pancreatic cancer. A Phase III trial of the National Cancer Institute of Canada Clinical Trials Group [NCIC-CTG]. Proc. Am. Soc. Clin. Oncol. Gastrointestinal Cancers Symposium (2005):Abstract 77.
   Google Scholar
• SHEPHERD FA, RODRIGUES PJ, CIULEANU T et al.:Erlotinib in previously treated non-small-cell lung cancer. N. Engl. J. Med. (2005) 353(2):123-132.
   PubMed Web of Science ®Google Scholar
• HERBST RS, PRAGER D, HERMANN R et al.: TRIBUTE – A Phase III trial of erlotinib HCl (OSI-774) combined with carboplatin and paclitaxel (CP) chemotherapy in advanced non-small cell lung cancer (NSCLC). J. Clin. Oncol. (2005) 23(25):5892-5899.
   PubMed Web of Science ®Google Scholar
• GATZEMEIER U, PLUZANSKA A, SZCZESNA A et al.: Results of a Phase III trial of erlotinib (OSI-774) combined with cisplatin and gemcitabine (GC) chemotherapy in advanced non-small cell lung cancer (NSCLC). J. Clin. Oncol. 2004 ASCO Ann. Meet. Proc. (Post-Meeting Edn) (2004) 22(14S):7010.
   Google Scholar
• CHINNAIYAN S, HUANG S, ARMSTRONG E et al.: Radiosensitization following EGFR signaling inhibition by erlotinib (Tarceva). Int. J. Rad. Onc. Biol. Phys. (2003) 57(Suppl. 1):S294.
   Google Scholar
• CONTESSA JN, ABELL A,VALERIE K, LIN PS, SCHMIDT-ULLRICH RK: ErbB receptor tyrosine kinase network inhibition radiosensitizes carcinoma cells. Int. J. Radiat. Oncol. Biol. Phys. (2006) 65(3):851-858.
   PubMed Web of Science ®Google Scholar
• HARARI P, HUANG SM: Combining EGFR inhibitors with radiation or chemotherapy: will preclinical studies predict clinical results? Int. J. Radiat. Oncol. Biol. Phys. (2004) 58(3):976-983.
   PubMed Web of Science ®Google Scholar
• IANNITTI D, DIPETRILLO T, AKERMAN P et al.: Erlotinib and chemoradiation followed by maintenance erlotinib for locally advanced pancreatic cancer: a Phase I study. Am. J. Clin. Oncol. (2005) 28(6):570-575.
   PubMed Web of Science ®Google Scholar
• KORTMANSKY JS, O’REILLY EM, MINSKY BD et al.: A Phase I trial of erlotinib, gemcitabine and radiation for patients with locally-advanced, unresectable pancreatic cancer. J. Clin. Oncol. 2005 ASCO Ann. Meet. Proc. (2005) 23(16S):4107.
   Google Scholar
• CIARDELLO F, CAPUTO K, BIANCO R et al.: Antitumor effect and potenation of cytotoxic drugs activity in hyman cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clin. Cancer Res. (2000) 6:2053-2063.
   PubMed Web of Science ®Google Scholar
• RABEN D, HELFRICH B, CHANS D et al.: ZD1839, a selective epidermal growth factor tyrosine kinase inhibitor enhances radiation induced cytotoxicty in human pancreatic and cholangiocarcinoma cell lines in vitro. Presented at the Gastrointestinal Cancer Research Conference, Orlando FL, USA, November 2000.
   Google Scholar
• HERBST RS, MADDOW AM, ROTHENBERG ML et al.: Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a Phase I trial. J. Clin. Oncol. (2002) 20:3815-3825.
   PubMed Web of Science ®Google Scholar
• CZITO BG, WILLETT CG, BENDELL JC et al.: Increased toxicity with gefitinib, capecitabine and radiation therapy in pancreatic and rectal cancer: Phase I trial results. J. Clin. Oncol. (2006) 24:656-662.
   PubMed Web of Science ®Google Scholar
• MAUREL J, MARTIN-RICHARD M, CONILL C et al.: Phase I trial of gefitinib with concurrent radiotherapy and fixed 2-h gemcitabine infusion in locally advanced pancreatic cancer. Int. J. Radiat. Oncol. Biol. Phys. (2006) 66:1391-1398.
   PubMed Web of Science ®Google Scholar
• CHEN H, RABEN D, SCHEFTER T et al.: KRAS mutation analysis in patients with locally advanced pancreatic cancer (LAPC) treated with gefitinib and chemoradiation therapy (CT-RT) in a Phase I trial. J. Clin. Oncol. 2006 ASCO Ann. Meet. Proc. Part I. (2006) 24(18S):4106.
   Google Scholar
• GIACCONE G, HERBST RS, MANEGOLD C et al.: Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a Phase III trial – Intact 1. J. Clin. Oncol. (2004) 22:777-784.
   PubMed Web of Science ®Google Scholar
• HERBST RS, GIACCONE G, SCHILLER JH et al.: Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a Phase III trial – intact 2. J. Clin. Oncol. (2004) 22:785-794.
   PubMed Web of Science ®Google Scholar
• GRUNWALD V, HIDALGO M: Developing inhibitors of the epidermal growth factor receptor for cancer treatment. J. Natl. Cancer Inst. (2003) 95(12):851-867.
   PubMed Web of Science ®Google Scholar
• WISSNER A, BRAWNER F, RABINDRAN SK, NILAKANTAN R et al.: Syntheses and EGFR and HER-2 kinase inhibitory activities of 4-anilinoquinoline-3-carbonitiriles: analogues of three important 4-anilinoquinazolines currently undergoing clinical evaluation as therapeutic antitumor agents. Bioorg. Med. Chem. Lett. (2002) 12(20):2893-2897.
   PubMed Web of Science ®Google Scholar
• ERLICHMAN C, HIDALGO M, BONI et al.: Phase I study of EKB-569, an irreversible inhibitor of the epidermal growth factor receptor, in patients with advanced solid tumors. J. Clin. Oncol. (2002) 24(115):2225-2226.
   Google Scholar
• MORGAN JA, BUKOWSKI RM, XIONG H et al.: Preliminary report of a Phase I study of EKB-569, an irreversitble inhibitor of the epidermal growth factor receptor (EGFR) given in combination with gemcitabine to patients with advanced pancreatic cancer. Proc. Am. Soc. Clin. Oncol. (2003) 22:197 (Abstract 788).
   Google Scholar
• XIA W, MULLIN RJ, KEITH BR et al.: Anti-tumor activity of lapatinib: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erB2 and downstream Erk1/2 and AKT pathways. Oncogene (2002) 21:6255-6263.
   PubMed Web of Science ®Google Scholar
• GRAUS-PORTA D, BEERLI RR, DALY JM et al.: ErbB2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. EMBO (1997) 16:1647-1655.
   PubMed Web of Science ®Google Scholar
• RUSNAK DW, LACKEY K, AFFLECK K et al.: The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, lapatinib, on the growth of human normal and tumor-derived cell lines in vitro and in vivo. Mol. Cancer Ther. (2001) 1:85-94.
   PubMed Web of Science ®Google Scholar
• BURGESS AW, CHO HS, EIGENBROT C et al.: An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors. Mol. Cell (2003) 12:541-552.
   PubMed Web of Science ®Google Scholar
• ASANO T, YAO Y, ZHU J et al.: The PI 3-kinase/Akt signaling pathway is activated due to aberrant Pten expression and targets transcription factors NF-κB and c-Myc in pancreatic cancer cells. Oncogene (2004) 23:8571-8580.
   PubMed Web of Science ®Google Scholar
• SAFRAN H, IANNITTI D, MINER T et al.: GW572016, gemcitabine and GW572016, gemcitabine, oxaliplatin, a two-stage, Phase I study for advanced pancreaticobiliary cancer. Proc. Am. Soc. Clin. Oncol. (2006) 24:179s (Abstract 4002).
   Google Scholar
• BRUNS CJ, HARBISON MT, DAVIS DW et al.: Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms. Clin. Cancer Res. (2000) 6(5):1936-1948.
   PubMed Web of Science ®Google Scholar
• OVERHOLSER JP, PREWETT MC, HOOPER AT et al.: Epidermal growth factor receptor blockade by antibody IMC-C225 inhibits growth of a human pancreatic carcinoma xenograft in nude mice. Cancer (2000) 89(1):74-82.
   PubMed Web of Science ®Google Scholar
• HUANG ZQ, BUCHSBAUM DJ, RAISCH KP et al.: Differential responses by pancreatic carcinoma cell lines to prolonged exposure to Erbitux (IMC-C225) anti-EGFR antibody. J. Surg. Res. (2003) 111(2):274-283.
   PubMed Web of Science ®Google Scholar
• ARNOLETTI JP, BUCHSBAUM DJ, HUANG ZQ et al.: Mechanisms of resistance to Erbitux (anti-epidermal growth factor receptor) combination therapy in pancreatic adenocarcinoma cells. J. Gastrointest. Surg. (2004) 8(8):960-969.
   PubMed Web of Science ®Google Scholar
• SCLABAS GM, FUJIOKA S, SCHMIDT S et al.: Restoring apoptosis in pancreatic cancer cells by targeting the nuclear factor-kappaB signaling pathway with the anti-epidermal growth factor antibody IMC-C225. J. Gastrointest. Surg. (2003) 7(1):37-43.
   PubMed Web of Science ®Google Scholar
• XIONG HQ, ROSENBERG A, LOBUGLIO A et al.: Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter Phase II trial. J. Clin. Oncol. (2004) 22(13):2610-2616.
   PubMed Web of Science ®Google Scholar
• LAMMERING G: Inhibition of the Type III epidermal growth factor receptor variant mutant receptor by dominant-negative EGFR-CD533 enhances malignant glioma cell radiosensitivity. Clin. Cancer Res. (2004) 10(19):6732-6743.
   PubMed Web of Science ®Google Scholar
• JENSEN AD, MUSCHER MW, BISCHOFF H et al.: Treatment of non-small cell lung cancer with intensity-modulated radiation therapy in combination with cetuximab: the NEAR protocol (NCT00115518). BMC Cancer (2006) 6(1):122.
   PubMedGoogle Scholar
• BAUMANN M, KRAUSE M: Targeting the epidermal growth factor receptor in radiotherapy: radiobiological mechanisms, preclinical and clinical results. Radiother. Oncol. (2004) 72(3):257-266.
   PubMed Web of Science ®Google Scholar
• BONNER JA, HARARI PM, GIRALT J et al.: Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N. Engl. J. Med. (2006) 354(6):567-578.
   PubMed Web of Science ®Google Scholar
• BOWERS G, REARDON D, HEWITT T et al.: The relative role of ErbB1-4 receptor tyrosine kinases in radiation signal transduction responses of human carcinoma cells. Oncogene (2001) 20(11):1388-1397.
   PubMed Web of Science ®Google Scholar
• RABEN D, HELFRICH B, CHAN DC et al.: The effects of cetuximab alone and in combination with radiation and/or chemotherapy in lung cancer. Clin. Cancer Res. (2005) 11(2 Pt 1):795-805.
   PubMed Web of Science ®Google Scholar
• KRAUSE C, SCHUTZE M, PETERSEN M: Different classes of EGFR inhibitors may have different potential to improve local tumour control after fractionated irradiation: a study on C225 in FaDu hSCC. Radiother. Oncol. (2005) 74(2):109-115.
   PubMed Web of Science ®Google Scholar
• LAMMERING G, VALERIE K, LIN PS et al.: Radiation-induced activation of a common variant of EGFR confers enhanced radioresistance. Radiother. Oncol. (2004) 72(3):267-273.
   PubMed Web of Science ®Google Scholar
• DENT P, REARDON DB, PARK JS et al.: Radiation-induced release of transforming growth factor alpha activates the epidermal growth factor receptor and mitogen-activated protein kinase pathway in carcinoma cells, leading to increased proliferation and protection from radiation-induced cell death. Mol. Biol. Cell. (1999) 10(8):2493-506.
   PubMed Web of Science ®Google Scholar
• TODD TG, MIKKELSEN RB, RORRER WK et al.: Ionizing radiation stimulates existing signal transduction pathways involving the activation of epidermal growth factor receptor and ERBB-3, and changes of intracellular calcium in A431 human squamous carcinoma cells. J. Recept. Signal Transduct. Res. (1999) 19(6):885-908.
   PubMed Web of Science ®Google Scholar
• SCHMIDT-ULLRICH RK, MIKKELSEN RB, DENT P et al.: Radiation-induced proliferation of the human A431 squamous carcinoma cells is dependent on EGFR tyrosine phosphorylation. Oncogene (1997) 15(10):1191-1197.
   PubMed Web of Science ®Google Scholar
• HUANG SM, HARARI PM: Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: inhibition of damage repair, cell cycle kinetics, and tumor angiogenesis. Clin. Cancer Res. (2000) 6(6):2166-2174.
   PubMed Web of Science ®Google Scholar
• KETTLEBOROUGH CA, SALDANHA J, HEATH VJ, MORRISON CJ, BENDIG MM: Humanization of a mouse monoclonal antibody by CDR-grafting: the importance of framework residues on loop conformation. Protein Eng. (1991) 4:773-783.
   PubMedGoogle Scholar
• BANGARD C, GOSSMANN A, PAPYAN A et al.: Magnetic resonance imaging in an orthotopic rat model: blockade of epidermal growth factor receptor with EMD72000 inhibits human pancreatic carcinoma growth. Int. J. Cancer (2005) 114(1):131-138.
   PubMed Web of Science ®Google Scholar
• BURGER AM, HEISS NS, KREYSCH HG et al.: The humanized monoclonal anti-EGFR antibody EMD72000 potently inhibits the growth of EGFR-expressing human tumor xenografts insensitive to chemotherapeutic drugs [abstract]. Proc. Am. Assoc. Cancer Res. (2002) 44:1139.
   Google Scholar
• AMENDT C, MANTELL O, PETERS M et al.: In vivo activity of humanized monoclonal anti-EGFR antibody EMD72000 in combination with gemcitabine on growth of primary pancreatic tumors and metastases in an orthotopic nude mouse model [abstract]. Proc. Am. Assoc. Cancer Res. (2003) 44(2):1234.
   Google Scholar
• VANHOEFER U, TEWES M, ROJO F et al.: Phase I study of the humanized antiepidermal growth factor receptor monoclonal antibody EMD72000 in patients with advanced solid tumors that express the epidermal growth factor receptor. J. Clin. Oncol. (2004) 22(1):175-184.
   PubMed Web of Science ®Google Scholar
• GRAEVEN U, KREMER B, SUEDHOFF TH et al.: Phase I study of the humanised anti-EGFR monoclonal antibody matuzumab (EMD 72000) combined with gemcitabine in advanced pancreatic cancer. Br. J. Cancer (2006) 94:1293-1299.
   PubMed Web of Science ®Google Scholar
• YANG XD, JIA XC, CORVALAN JC et al.: Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy. Crit. Rev. Oncol. Hematol. (2001) 38:17-23.
   PubMed Web of Science ®Google Scholar
• FOON KA, YANG XD, WEINER LM et al.: Preclinical and clinical evaluations of ABX-EGF, a fully human anti-epidermal growth factor receptor antibody. Int. J. Radiat. Oncol. Biol. Phys. (2004) 58(3):984-990.
   PubMed Web of Science ®Google Scholar
• LYNCH DH, YANG XD: Therapeutic potential of ABX-EGF: A fully human anti-epidermal growth factor receptor monoclonal antibody for cancer treatment. Semin. Oncol. (2002) 29(1 Suppl. 4):47-50.
   PubMed Web of Science ®Google Scholar
• JIA XC, CORVALAN JRF, ZHANG L et al.: Inhibition of vascular endothelial cell growth factor and interleukin-8 production in tumor and endothelial cell lines by a fully human monoclonal antibody to epidermal growth factor receptor. Proc. Ann. Meet. Am. Assoc. Cancer Res. (2000):290.
   Google Scholar
• FIGLIN RA, BELLDEGRUN AS, CRAWFORD J et al.: ABX-EGF, a fully human anti-epideral growth factor receptor (EGFR) monoclonal antibody (mAb) in patients with advanced cancer: Phase I clinical results. Proc. Am. Soc. Clin. Oncol. (2002) 21:Abstract 35.
   Web of Science ®Google Scholar
• YAMANAKA Y, FRIESS H, KOBRIN MS et al.: Overexpression of HER-2/neu oncogene in human pancreatic carcinoma. Hum. Pathol. (1993) 24(10):1127-1134.
   PubMed Web of Science ®Google Scholar
• HALL PA, HUGHES CM, STADDON SL et al.: The c-erbB-2 proto-oncogene in human pancreatic cancer. J. Pathol. (1990) 161(3):195-200.
   PubMed Web of Science ®Google Scholar
• SATOH K, SASANO H, SHIMOSEGAWA T et al.: An immunohistochemical study of the c-erbB-2 oncogene product in intraductal mucin- hypersecreting neoplasms and in ductal cell carcinomas of the pancreas. Cancer (1993) 72(1):51-56.
   PubMed Web of Science ®Google Scholar
• LEI S, APPERT SE, NAKATA B et al.: Overexpression of HER-2/neu oncogene in pancreatic cancer correlates with shortened survival. Int. J. Pancreatol. (1995) 17:15-21.
   PubMedGoogle Scholar
• SAFRAN H, STEINHOFF M, MANGRAY S et al.: Overexpression of the HER-2/neu oncogene in pancreatic adenocarcinoma. Am. J. Clin. Oncol. (2001) 24:496-499.
   PubMed Web of Science ®Google Scholar
• SAFRAN H, IANNITTI D, RAMANATHAN R et al.: Herceptin and gemcitabine for metastatic pancreatic cancers that overexpress HER-2/neu. Cancer Invest. (2004) 22(5):706-712.
   PubMed Web of Science ®Google Scholar
• LYNCH TJ, BELL DW, SORDELLA R et al.: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. (2004) 350:2129-2139.
   PubMed Web of Science ®Google Scholar
• PAEZ JG, JANNE PA, LEE JC et al.: EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science (2004) 304:1497-1500.
   PubMed Web of Science ®Google Scholar
• RAYMOND E, FAIVRE S, ARMAND JP: Epidermal growth factor receptor tyrosine kinase as a target for anticancer therapy. Drugs (2000) 60(Suppl. 1):15-23.
   PubMed Web of Science ®Google Scholar
• PAO W, MILLER V, ZAKOWSKI M et al.: EGF receptor gene mutations are common in lung cancers from ‘never smokers’ and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc. Natl. Acad. Sci. USA (2004) 101:13306.
   PubMed Web of Science ®Google Scholar
• TOKUMO M, TOYOOKA S, KIURA K et al.: The relationship between epidermal growth factor receptor mutations and clinicopathologic features in non-small cell lung cancers. Clin. Cancer Res. (2005) 11(3):1167.
   PubMed Web of Science ®Google Scholar
• KWAK E, JANKOWSKI J, THAYER SP et al.: Epidermal growth factor receptor kinase domain mutations in esophageal and pancreatic adenocarcinomas. Clin. Cancer Res. (2006) 12(14 Pt 1):4283-4287.
   PubMed Web of Science ®Google Scholar
• IMMERVOLL H, HOEM D, KUGARADJH K, STEINE SJ, MOLVEN A: Molecular analysis of the EGFR-RAS-RAF pathway in pancreatic ductal adenocarcinomas: lack of mutations in the BRAF and EGFR genes. Virchows Arch. (2006) 448(6):788-796.
   PubMed Web of Science ®Google Scholar
• EBERHARD DA, JOHNSON BE, AMLER LC et al.: Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J. Clin. Oncol. (2005) 23(25):5900-5909.
   PubMed Web of Science ®Google Scholar
• AVIEL-RONEN S, FIONA H, BLACKHALL FH, SHEPHERD FA, TSAO MS: K-ras Mutations in non-small-cell lung carcinoma: a review. Clin. Lung Cancer (2006) 8(1):30-38.
   PubMed Web of Science ®Google Scholar
• LOHR M, KLOPPEL G, MAISONNEUVE P, LOWENFELS AB, LUTTGES J: Frequency of K-ras mutations in pancreatic intraductal neoplasias associated with pancreatic ductal adenocarcinoma and chronic pancreatitis: a meta-analysis. Neoplasia (2005) 7:17-23.
   PubMed Web of Science ®Google Scholar
• HRUBAN RH, GOGGINS M, PARSONS J, KERN SE: Progression model for pancreatic cancer. Clin. Cancer Res. (2000) 6(8):2969-2972.
   PubMed Web of Science ®Google Scholar
• ROZENBLUM E, SCHUTTE M, GOGGINS M et al.: Tumor-suppressive pathways in pancreatic carcinoma. Cancer Res. (1997) 57:1731-1734.
   PubMed Web of Science ®Google Scholar
• BIANCO R, SHIN I, RITTER C et al.: Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors. Oncogene (2003) 22(18):2812-2822.
   PubMed Web of Science ®Google Scholar
• VAZQUEZ F, SELLER WR: The PTEN tumor suppressor protein: an antagonist of phosphor-inositide 3-kinase signaling. Biochem. Biophys. Acta (2000) 1470:M21-M35.
   PubMedGoogle Scholar
• MELLINGHOFF I, WANG M, VIVANCO I et al.: Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N. Engl. J. Med. (2005) 353(19):2012-2024.
   PubMed Web of Science ®Google Scholar